Table 4 Prescribed medications for asthma
|  | Study population N = 101 |
|---|---|
OCS | N (%) 20 (19.8%) |
Corticosteroids burst treatment/short course | N (%) 79 (78.2%) |
ICS/LABA | N (%) 101 (100.0%) |
Active substances | N (%) |
 Budesonide/Formoterol | 57 (56.4%) |
 Fluticasone/Salmeterol | 17 (16.8%) |
 Fluticasone/Vilanterol | 8 (7.9%) |
 Beclomethasone/Formoterol | 7 (6.9%) |
 Other | 12 (11.9%) |
Total daily ICS dose | N = 100 |
 Low dose | 0 (0.0%) |
 Medium dose | 34 (34.0%) |
 High dose | 66 (66.0%) |
Time since initiation of ICS/LABA, in years | Â |
 Mean ± SD | 4.5 ± 4.3 |
 Range | 0–19.2 |
 Median | 2.9 |
|  | N = 82 |
Other maintenance treatments | N (%) |
 Leukotriene receptor antagonists | 58 (70.7%) |
 Anticholinergics | 36 (43.9%) |
 Glucocorticoids | 27 (32.9%) |
 Systemic anti-histamines | 20 (24.4%) |